Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.38 |
| ▸ | CNR1 | P21554 | 6/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676735 | 0.82 | MAPK14 (0.37) | CNR2HMGCRALDH1A1KDRKDM4E | |
| SCHEMBL13391465 | 0.79 | HMGCR (0.33) | HMGCR | |
| SCHEMBL9947014 | 0.78 | CNR2 (0.39) | CNR2CNR1ALDH1A1MAPT | |
| SCHEMBL1012596 | 0.78 | CNR2 (0.39) | CNR2CNR1 | |
| SCHEMBL17796648 | 0.78 | CYP1A2 (0.38) | CNR2CNR1ALDH1A1KDRKDM4E | |
| SCHEMBL431491 | 0.77 | ALDH1A1 (0.42) | CNR2ALDH1A1KDRKDM4EMAPT | |
| SCHEMBL9891487 | 0.77 | EGFR (0.42) | CNR2CNR1ALDH1A1 | |
| SCHEMBL9713593 | 0.77 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL9892807 | 0.76 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL14723928 | 0.76 | CNR2 (0.40) | CNR2CNR1HMGCRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158384-A1 | CB2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-05-16 | — | — | US | disclosed |
| US-20240092769-A1 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2022132803-A1 | CB2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022132803-A1 | CB2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220135554-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
| US-11084810-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200262830-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2020-08-20 | — | — | US | disclosed |
| US-10570125-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190161481-A1 | Novel (Cyano-Dimethyl-Methyl)-Isoxazoles and -[1,3,4]Thiadiazoles | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-05-30 | — | — | US | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| WO-2010036630-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036630-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262830-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885HMGCR 3429/4885 |
| US-20240158384-A1 | CB2 RECEPTOR AGONISTS | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885HMGCR 3693/4885 |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885HMGCR 3061/4885 |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885HMGCR 3504/4885 |
| US-20240092769-A1 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885HMGCR 3061/4885 |
| US-10570125-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885HMGCR 3061/4885 |
| US-11084810-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885HMGCR 3061/4885 |
| US-20190161481-A1 | Novel (Cyano-Dimethyl-Methyl)-Isoxazoles and -[1,3,4]Thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885HMGCR 3429/4885 |
| US-20220135554-A1 | NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885HMGCR 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.